Evidence map›Paper›PMID 35595781›Full record

Trial reportScientific reports2022

Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction.

Nicolas Girerd, John Cleland, Stefan D Anker, William Byra, Carolyn S P Lam, David Lapolice, Mandeep R Mehra, Dirk J van Veldhuisen, Emmanuel Bresso, Zohra Lamiral and 2 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Omics research in atherosclerosis.Molecular and cellular biochemistry · 2025
    Review
  10. Article
  11. Connecting intermediate phenotypes to disease using multi-omics in heart failure.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Proteomic Associations of Adverse Outcomes in Human Heart Failure.Journal of the American Heart Association · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 6 countries.

Nicolas GirerdUniversité de Lorraine, Centre d'Investigation Clinique-Plurithématique Inserm CIC-P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
John ClelandRobertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, Scotland.
Stefan D AnkerDepartment of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
William ByraJanssen Research and Development, Raritan, NJ, USA.
Carolyn S P LamNational Heart Centre Singapore, Duke-National University of Singapore, Singapore, Singapore.
David LapoliceJanssen Research and Development, Raritan, NJ, USA.
Mandeep R MehraBrigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Dirk J van VeldhuisenDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Emmanuel BressoUniversité de Lorraine, Centre d'Investigation Clinique-Plurithématique Inserm CIC-P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Zohra LamiralUniversité de Lorraine, Centre d'Investigation Clinique-Plurithématique Inserm CIC-P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Barry GreenbergCardiology Division, Department of Medicine, University of California, La Jolla, San Diego, USA.
Faiez ZannadUniversité de Lorraine, Centre d'Investigation Clinique-Plurithématique Inserm CIC-P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. f.zannad@chru-nancy.fr.
Inserm · FRJanssen (United States) · USBerlin-Brandenburger Centrum für Regenerative Therapien · DEBrigham and Women's Hospital · USCentre d'Investigation Clinique Pierre Drouin · FRNational University of Singapore · SGUniversity Medical Center Groningen · NLUniversity of California San Diego · USUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with heart failure (HF) and coronary artery disease (CAD) have a high risk for cardiovascular (CV) events including HF hospitalization, stroke, myocardial infarction (MI) and sudden cardiac death (SCD). The present study evaluated associations of proteomic biomarkers with CV outcome in patients with CAD and HF with reduced ejection fraction (HFrEF), shortly after a worsening HF episode. We performed a case-control study within the COMMANDER HF international, double-blind, randomized placebo-controlled trial investigating the effects of the factor-Xa inhibitor rivaroxaban. Patients with the following first clinical events: HF hospitalization, SCD and the composite of MI or stroke were matched with corresponding controls for age, sex and study drug. Plasma concentrations of 276 proteins with known associations with CV and cardiometabolic mechanisms were analyzed. Results were corrected for multiple testing using false discovery rate (FDR). In 485 cases and 455 controls, 49 proteins were significantly associated with clinical events of which seven had an adjusted FDR < 0.001 (NT-proBNP, BNP, T-cell immunoglobulin and mucin domain containing 4 (TIMD4), fibroblast growth factor 23 (FGF-23), growth differentiation factor-15 (GDF-15), pulmonary surfactant-associated protein D (PSP-D) and Spondin-1 (SPON1)). No significant interactions were identified between the type of clinical event (MI/stroke, SCD or HFH) and specific biomarkers (all interaction FDR > 0.20). When adding the biomarkers significantly associated with the above outcome to a clinical model (including NT-proBNP), the C-index increase was 0.057 (0.033-0.082), p < 0.0001 and the net reclassification index was 54.9 (42.5 to 67.3), p < 0.0001. In patients with HFrEF and CAD following HF hospitalization, we found that NT-proBNP, BNP, TIMD4, FGF-23, GDF-15, PSP-D and SPON1, biomarkers broadly associated with inflammation and remodeling mechanistic pathways, were strong but indiscriminate predictors of a variety of individual CV events.

Indexed as

Atrial RemodelingCoronary Artery DiseaseHeart FailureInflammationMyocardial InfarctionStrokeVentricular Dysfunction, LeftBiomarkersCase-Control StudiesDeath, Sudden, CardiacGrowth Differentiation Factor 15HumansNatriuretic Peptide, BrainPeptide FragmentsProteomicsStroke VolumeBiomarkersGrowth Differentiation Factor 15Natriuretic Peptide, BrainPeptide Fragments

Identifiers

PMID35595781
PMCPMC9123183
OpenAlexW4281258683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.